REPLIGEN CORP Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31)
REPLIGEN CORP (RGEN) reported Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31) of $10.00 thousand for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-14.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses · last filed 2014-03-14
- REPLIGEN CORP available-for-sale securities, continuous unrealized loss position, aggregate loss (deprecated 2018-01-31) for the quarter ending 2013-09-30 was $3.00K.
- REPLIGEN CORP available-for-sale securities, continuous unrealized loss position, aggregate loss (deprecated 2018-01-31) for the quarter ending 2013-06-30 was $5.00K.
- REPLIGEN CORP available-for-sale securities, continuous unrealized loss position, aggregate loss (deprecated 2018-01-31) for fiscal 2013 was $10.00K.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31) 3 month | Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31) 6 month | Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31) 12 month |
|---|---|---|---|
| 2013-12-31 | $10.00K 10-K · filed 2014-03-14 | ||
| 2013-09-30 | $3.00K 10-Q · filed 2013-11-08 | $8.00K derived: sum of 2 quarters · filed 2013-11-08 | |
| 2013-06-30 | $5.00K 10-Q · filed 2013-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |